Adverum Biotechnologies to Present at Upcoming Conferences
| Event: | The 29th Annual Piper Jaffray Healthcare Conference | |
| Date: | November 28, 2017 | |
| Time: | 12:10 – 12:30 p.m. ET | |
| Location: | New York, NY | |
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | |
| Event: | Barclays Gene Editing & Gene Therapy Summit | |
| Date: | November 30, 2017 | |
| Time: | 9:00 – 9:20 a.m. ET | |
| Location: | New York, NY | |
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | |
A live and replay audio webcast of the
About
Adverum is a leading gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Adverum Contact:Leone Patterson Chief Financial Officer 650-665-7222 lpatterson@adverum.com
Source: Adverum Biotechnologies, Inc.